Industry Economy TECH GAME
Society Comfort AUTO MEDIA

AprilBio-Celros Biotech Signs a Joint Research Agreement for Inflammatory Bowel Disease (IBD) Dual Antibody Treatment

  • Wednesday, March 25, 2020, 1:20 pm
  • ACROFAN=Seunghee Shin
 On April 24, AprilBio, the new drug bio venture, announced that it has signed a joint research agreement with Celros Biotech, the inflammatory drug development company, for dual antibody treatment of inflammatory bowel disease (hereinafter IBD).

Both companies plan to develop therapeutics using Celros Biotech's antibody and inflammation control source technology, and AprilBio's anti-Serum Albumin Fab-Associated (SAFA) platform source technology and antibody conjugation technology.


Inflammatory bowel disease is a disease in which abnormal chronic inflammation in the large and small intestine improves and recurs repeatedly. The therapeutic efficacy of current therapeutic antibodies is only 30%, so unmet medical demand is high.

The agreement presents a new concept that the therapeutic effect can be significantly improved by stably double-binding the antibody developed by Celros Biotech with the existing SAFA technology of AprilBio.

"SAFA technology is a platform technology applicable to various drugs and mechanisms, so the effectiveness of SAFA technology can be highly appreciated through the joint development of innovative new drugs for IBD," said Sang-Hoon Cha, CEO at AprilBio.

"We are pleased to cooperate with AprilBio, which has abundant experience and source technology in double-antibody binding. We hope not only to discover new anti-drug candidates effective for the treatment of IBD, but also to continue to cooperate and develop global innovative new drugs with AprilBio in the future," said Yoon-Soo Bae, CEO at Celros Biotech.